Edwards Lifesciences Corp
For the period ended Jun 30, 2025. Filed Aug 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
During the second quarter of 2025, the following is a list of activity by our executive officers or directors with respect to a 10b5-1 trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (each, a “Plan”):
On July 29, 2025, Scott B. Ullem, Corporate Vice President, Chief Financial Officer, entered into a Plan providing for the potential sale of 59,700 shares of the Company’s stock commencing November 6, 2025. Mr. Ullem's Plan terminates on the earlier of April 9, 2026, or the date all shares are sold.
On July 30, 2025, Daniel J. Lippis, Corporate Vice President, Japan, Greater China and Asia Pacific, entered into a Plan providing for the potential sale of 7,134 shares of the Company’s stock commencing November 3, 2025. Mr. Lippis's Plan terminates on the earlier of May 1, 2026, or the date all shares are sold.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.